Abstract library

136 results for "Femia".
#1014 Sunitinib Induced Hypocalcaemia During Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used for pNET treatment.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Krystallenia Alexandraki
#275 The Use of Guar Gum in the Medical Management of Hyperinsulinaemic Hypoglycaemia
Introduction: Medical therapy, including guar gum, is frequently required in the management of patients with endogenous hyperinsulinaemic hypoglycaemia (e.g. insulinoma), especially if surgery is not appropriate.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
Authors: Carroll R W, Todd J F, ...
#810 Pancreatic Neuroendocrine Tumor Presenting in Pregnancy with Severe Hypercalcemia
Introduction: Malignant hypercalcemia secondary to pancreatic neuroendocrine tumor (pNET) is a rare occurrence with no standard management. We report a challenging case of pNET presenting during pregnancy and complicated by severe hypercalcemia.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: MD Rita E Assi
Authors: Assi R E, Shamseddine A, ...
#1295 Intra-Operative Portal Vein Insulin Assay Combined with Occlusion of the Pancreas for Complicated Pancreatogenous Hypoglycemia
Introduction: Pancreatogenous hypoglycemia is a rare endocrine disorder. The precise localization of hypersecreting tissue and determination of complete resection are two main challenges for complicated pancreatogenous hypoglycemia, such as multiple endocrine neoplasia syndromes type-1 (MEN-1) and nesidioblastosis.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Yang Zhiying
Authors: Yang Z, Tan H, Sun Y, Si S, ...
#2223 Diagnostic Dilemma in a Patient with Recurrent Hypoglycaemia: An Unusual Case
Introduction: Recurrent hypoglycemia is a part of Whipple’s triad and usually points towards insulinoma as a cause. Presence of metastasis is uncommon in Insulinoma, and other causes should be ruled out.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Gunjan Desai
Authors: Desai G, Pande P, Shah R, Palepu J, ...
#2774 Metastatic Merkel Cell Carcinoma Associated Paraneoplastic Hyponatraemia: Response to Avelumab
Introduction: Merkel cell carcinoma (MCC) is rare, encompassing primary cutaneous neuroendocrine carcinoma.It has an aggressive natural history, and exhibits high response rates to radiotherapy & chemotherapy but often of short duration.
Conference: 17th Annual ENETS Conference (2020)
Category: Case reports
Presenting Author: Dr Elspeth Saunders
Authors: Saunders E, Demirel S, Kim S, Skelly R, ...
#2949 Sunitinib May Be an Effective Treatment for Hypercalcemia Due To a Metastatic Pancreatic Neuroendocrine Tumor
Introduction: Malignant hypercalcemia due to neuroendocrine tumor(NET) is rare, and only a few reports are available in the literature.
Conference: 17th Annual ENETS Conference (2020)
Category: Case reports
Presenting Author: Prof. Huang-Ying Tan
Authors: Wang C, Qi Z, Tan H D, Tan H Y, ...
#431 Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma
Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels<30 mg/dl, insulin 150 microUI/ml, and C-peptide at upper normal limits. Endocrinologist prescribed prednisone, diazoxide and recombinant glucagon for hypoglicemic crisis, with little benefit. In March 2010, the patient was given radio-labelled Lu-177-OCTREOTATE treatment. After three cycles, hypoglicemic symptoms were still uncontrolled. CT scan showed stable disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Anna Ferrero
Authors: Ferrero A, Bellini E, Brizzi M P, Pia A, ...
#483 Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten)
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Miss Valérie Bernard
#1903 Hypoglycemias Appearing in a Patient Suffering from Poorly Differentiated Neuroendocrine Tumor for Three Years.
Introduction: Insulinomas are the most common functional PNENs and they have a weak malignant potential (<10%)
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Maxime Deslé
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team